Monopar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 10
- Market Cap
- $8.4M
- Introduction
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- Conditions
- CancerSolid TumorSolid Tumor CancerOncologyuPAR-positive Solid TumorUrokinase Plasminogen Activator Receptor-positive Solid Tumor
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Registration Number
- NCT06980519
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- Conditions
- CancerSolid TumorSolid Tumor, Adult
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Registration Number
- NCT06980506
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Conditions
- Solid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric CancerOvarian CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT06617169
- Locations
- 🇦🇺
Melbourne Theranostic Innovation Centre (MTIC), North Melbourne, Victoria, Australia
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Conditions
- Ovarian CancerPancreatic CancerSolid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric Cancer
- Interventions
- Diagnostic Test: PET/CT Diagnostic Imaging
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT06337084
- Locations
- 🇦🇺
Melbourne Theranostic Innovation Centre (MTIC), North Melbourne, Victoria, Australia
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT05043649
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Washington Medicine Fred Hutchinson Cancer Center, Seattle, Washington, United States
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
- Conditions
- Chemoradiotherapy-Induced Severe Oral Mucositis
- Interventions
- Drug: Placebo Mucoadhesive Buccal Tablet
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Monopar Therapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT04648020
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States